Subcutaneous IVIG now available

Article

ZLB Behring has received FDA approval for the first subcutaneous immunoglobulin, Vivaglobin (Immune Globulin Subcutaneous [Human]), indicated for the treatment of patients with primary immunodeficiency. According to the company, patients can safely self-administer the immunoglobulin and the drug may be appropriate for those who cannot tolerate the intravenous products due to poor venous access or side effects. Portable pumps can be used by the patient to deliver their weekly doses.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
2 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.